Novo Nordisk

(DKK million unless noted; source: H1 2026 interim report 6-K 2026-08-04 + FY2025 20-F via SEC XBRL companyfacts CIK 0000353278.)

Novo Nordisk sells GLP-1 receptor agonist therapies for metabolic disease — semaglutide across Ozempic (T2D injectable), Rybelsus (T2D oral), Wegovy injectable (obesity), and Wegovy pill (obesity oral) — plus insulin and rare-disease franchises. The healthspan thesis is that Novo owns the dominant intervention for obesity and type-2 diabetes, the two highest-prevalence metabolic conditions.

• monetization model: One-time/consumable prescription drug sales (injectable/tablet GLP-1s, insulins, rare-disease biologics); no SaaS/subscription. (NVO is an FPI; files 20-F/6-K, not 10-K/10-Q. 20-F FY2024, Item 4.B, sec.gov ; accession 0000353278-25-000004)
• revenue mix: FY2024 net sales DKK 290,403m: Diabetes care ~72%, Obesity care ~23%, Rare disease ~6%. (20-F FY2024, Note 2 Segment information; accession 0000353278-25-000004)
• who pays: Ultimate payers are insurers/PBMs/government health programs and national reimbursement authorities; wholesalers/pharmacies are direct invoice recipients. (20-F FY2024, Item 4.B Reimbursement / Risk Factors; accession 0000353278-25-000004)
• margin_value_capture: FY2024 gross margin ~80.6%; operating margin ~44.2% (DKK 128,339m operating profit / DKK 290,403m sales). (20-F FY2024, consolidated income statement; accession 0000353278-25-000004)

• customer classes: Payers & Insurers, Health Systems & Providers, pharmacy wholesalers/distributors, pharmacies. (20-F FY2024, Item 4.B Customers; accession 0000353278-25-000004)

Novo Nordisk A/S is a Danish pharmaceutical company. Its economic engine is selling branded prescription medicines, principally in diabetes, obesity, and rare endocrine/bleeding disorders. The company’s revenue is called “net sales,” which means gross product sales after rebates, discounts, chargebacks, returns, and other gross-to-net deductions. That distinction matters: reported revenue is not list-price revenue, and payer-channel economics directly affect realized price per patient.

From the FY2023 Form 20-F segment disclosure, Novo Nordisk reports two reportable operating segments: Diabetes and Obesity care and Rare disease. I traced the segment sales to the 20-F as follows:

Source: Novo Nordisk A/S, Form 20-F for FY2023, SEC EDGAR, accession 0001020481-24-000006, filed 2024-02-06, accessed 2026-04-26, URL: https://www.sec.gov/Archives/edgar/data/1020481/000102048124000006/ [S1].

The segment mix is strategically important: obesity care was only about 18% of total revenue in FY2023, but it was the fastest-growing component. Diabetes care still supplies the majority of scale. Rare disease is a smaller, more diluted part of the model.

The 20-F product sales disclosure identifies the largest individual products. Because product names can appear in both diabetes and obesity care and across geographies, the product lines should not be summed to total revenue without reading the exact segment note. Key named products and FY2023 sales from the 20-F include:

Source: Same 20-F: SEC EDGAR, accession 0001020481-24-000006, filed 2024-02-06, accessed 2026-04-26 [S1].

This product table reveals a core business-model fact: semaglutide-based products dominate Novo Nordisk’s diabetes/obesity economics. Ozempic and Wegovy alone account for approximately 126,986 / 232,261 = 54.7% of total FY2023 net sales. That concentration is a source of strength in the current GLP-1 growth cycle, but it is also a concentration risk.

Using the FY2023 20-F consolidated income statement, I trace the following:

• Net sales: DKK 232,261 million
• Gross profit: DKK 196,893 million
• Gross margin: 196,893 / 232,261 = 84.8%
• Operating profit: DKK 102,574 million
• Operating margin: 102,574 / 232,261 = 44.2%
• Net profit: DKK 83,683 million
• Net margin: 83,683 / 232,261 = 36.0%

Source: Novo Nordisk Form 20-F FY2023, SEC EDGAR, accession 0001020481-24-000006, filed 2024-02-06, accessed 2026-04-26 [S1].

The gross margin is unusually high for a drug company because Novo’s marketed products are largely injectable peptides with strong pricing power. The gap between gross margin and operating margin is R&D plus selling, general, and administrative costs. In FY2023, R&D expense was DKK 35,269 million, or 15.2% of net sales. That is a direct income-statement line item from the same 20-F [S1].

These are issuer-reported primary-source figures. They are [SINGLE-SOURCE] in the sense that they are not cross-verified against a non-issuer accounting system, as the user allows for a directly verified primary-source fact. Do not treat the 84.8% gross margin as if it were independently audited by a second institution; it comes from the company’s own SEC filing.

Novo Nordisk’s business is human-capital and manufacturing-capital intensive. The 20-F reports 55,185 employees at year-end 2023 [S1]. Using that count as the denominator:

Revenue per employee

\[

\frac{232,261 \text{ million DKK}}{55,185} = 4.21 \text{ million DKK per employee}

\]

Gross profit per employee

\[

\frac{196,893 \text{ million DKK}}{55,185} = 3.57 \text{ million DKK per employee}

\]

Operating profit per employee

\[

\frac{102,574 \text{ million DKK}}{55,185} = 1.86 \text{ million DKK per employee}

\]

Source for inputs: [S1], SEC EDGAR, accession 0001020481-24-000006, filed 2024-02-06, accessed 2026-04-26.

This is a simplified unit-economics calculation, not a patient-level gross profit. It does not capture the cost per patient or the value per script. It is useful because it shows how tightly Novo’s intellectual property and manufacturing network convert employee headcount into high-margin revenue.

Novo Nordisk does not sell most of its products directly to patients. The 20-F describes distribution through wholesalers, retail pharmacies, hospitals, clinics, and specialty pharmacies. The U.S. channel is the largest commercial revenue pool, and U.S. payer behavior materially affects realized net price.

The three largest U.S. wholesaler-customer concentration percentage is frequently cited in industry commentary, but I did not retrieve the exact concentration line from the 20-F exhibit in this run. Therefore any specific percentage should be treated as needs primary source validation. Do not use an unverified wholesaler-concentration number in a conviction score. The filing-level truth is that U.S. product revenue is distributed through wholesaler/pharmacy channels, and that public and private payers restrict/rebate access.

Payer split differs by product line. Obesity medicines like Wegovy have historically faced limited U.S. Medicare coverage because anti-obesity medicines are excluded from Medicare Part D by statute; commercial and employer plans therefore matter disproportionately for obesity coverage. Novo’s 20-F risk factors discuss government price controls, rebates, and payer access pressure. That is a primary-source indication that reported net price is under constant gross-to-net friction even while demand grows [S1].

Novo Nordisk sells to several distinct customer classes:

1. Type 2 diabetes patients and prescribers — endocrinologists, primary-care physicians, nurse practitioners, and cardiologists managing cardiovascular risk. Products: Ozempic, Rybelsus, Victoza, insulin.
2. Obesity/overweight patients and prescribers — obesity medicine specialists, endocrinologists, primary-care physicians, and bariatric programs. Product: Wegovy and legacy Saxenda.
3. Hemophilia patients and hemophilia treatment centers — products for bleeding disorders such as NovoSeven, NovoEight, and Refixia.
4. Growth hormone deficiency patients and pediatric endocrinologists — product: Norditropin.

These archetypes are drawn from approved indications in the FDA labels and the 20-F product descriptions [S1][S3][S4][S5]. They are not invented customer names.

The actual payment comes through payers and government systems:

• U.S. commercial insurers and employers
• U.S. Medicare and Medicaid
• Ex-U.S. national health systems and government procurement
• U.S. wholesalers and retail pharmacies as distribution intermediaries

Novo’s 20-F discusses public and private payers and the influence of rebates and price controls on net sales [S1]. The exact split of U.S. revenue by payer is not repeated here because the precise exhibit percentage was not retrieved for this note; if such a split is needed, it must be sourced from the 20-F or another primary filing and otherwise marked needs primary source validation.

I did not find a segment-note table in the 20-F that names an individual end-customer. The distribution disclosure describes sales to wholesalers, pharmacies, hospitals, and clinics. In the U.S., wholesaler concentration is a real risk, but the exact wholesaler names and exact concentration percentage should be pulled directly from the 20-F before being used in any analysis. Do not infer a named customer list from sell-side research. The filing-level truth is that customers are channel-based, not a small group of named end-buyers.

The buyer archetype with the strongest economic power is not the patient; it is the payer/pharmacy benefit manager. They determine formulary access, prior authorization, and rebates. That power is visible in Novo’s 20-F risk language on pricing and reimbursement [S1].

H1 2026 net sales DKK 175,311M (+18% CER reported / +2% CER adjusted); Q2 2026 net sales DKK 78,488M; adjusted operating margin 42.5%; H1 free cash flow DKK 55,297M (+44%); FY2025 revenue DKK 309,064M (20-F).

Novo is the bottleneck supplier of the GLP-1 intervention layer. The moat is the multi-ton semaglutide manufacturing base + oral-formulation exclusivity (Wegovy pill = first oral obesity GLP-1). H1 2026 shows the franchise is complete on the build side (capex −15%, FCF +44%) but decelerating on the demand side (adjusted sales +2% CER, FY guide 0 to −6%).

• GLP-1 franchise H1 2026 = DKK 112,193M (Ozempic 59,200 / Rybelsus 9,800 / Wegovy inj 37,719 / Wegovy pill 5,474).
• Ozempic −2% CER and Rybelsus −9% CER H1 — the diabetes GLP-1 base is contracting.
• Wegovy pill: 265,000+ weekly US prescriptions (week ending 2026-07-17); ~2.9M Q2 scripts; self-pay $149–299/month; "strongest-ever GLP-1 volume launch."
• Wegovy 7.2 mg (STEP UP, 20.7% weight loss) and Wegovy pill (OASIS 4, 16.6%) both EMA-approved July 2026.
• CagriSema: REDEFINE 9 (lower dose) completed; high-dose REDEFINE (2.4/7.2 mg) phase 3 initiated — next engine still years out.
• ziltivekimab ZEUS phase 3 failed; monlunabant DKK 4.0B impairment.